PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort
Author:
Backeljauw Philippe1, Miller Bradley S.2, Levy Richard3, McCormick Kenneth4, Zouater Hichem5, Zabransky Markus5, Campbell Kim6
Affiliation:
1. Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine , Cincinnati , OH , USA 2. Department of Pediatrics , Division of Pediatric Endocrinology, University of Minnesota , Minneapolis , MN , USA 3. Rush University Medical Center , Chicago , IL , USA 4. Division of Endocrinology, University of Alabama at Birmingham , Birmingham , AL , USA 5. Sandoz GmbH , Holzkirchen , Germany 6. Sandoz Inc. , Princeton , NJ , USA
Abstract
Abstract
Objectives
Omnitrope® (somatropin, Sandoz Inc.) is one of several recombinant human growth hormones (rhGH) approved in the United States (US) for use in pediatric indications, including growth hormone deficiency (GHD) and idiopathic short stature (ISS). We report data on the effectiveness and safety of Omnitrope® in the US cohort of the PATRO Children (international, longitudinal, non-interventional) study.
Methods
All visits and assessments are carried out according to routine clinical practice, and doses of Omnitrope® are given according to country-specific prescribing information.
Results
By September 2018, 294 US patients were recruited; the two largest groups were GHD (n=193) and ISS (n=62). Across all indications, HSDS improvement (ΔHSDS) from baseline at three years was +1.0 (rhGH-naïve, +1.2; pre-treated, +0.7). In pre-pubertal patients, ΔHSDS from baseline at three years was +0.94 (rhGH-naïve, +1.3; pre-treated, +0.7). Following three years of treatment, ΔHSDS from baseline was +1.3 in rhGH-naïve GHD patients and +1.1 in rhGH-naïve ISS patients. In pre-pubertal rhGH-naïve patients, ΔHSDS from baseline was +1.3 and +1.2 in GHD and ISS patients, respectively. Overall, 194 patients (66.0%) experienced adverse events (AEs; n=886 events); most were of mild-moderate intensity. Five patients (1.7%) had AEs that were suspected to be treatment-related (n=5 events). All reported neoplasms were benign, non-serious, and considered unrelated to rhGH therapy. No AEs of diabetes mellitus or hyperglycemia were reported.
Conclusions
Omnitrope® appears to be well tolerated and effective in the majority of patients, without evidence of an increased risk of developing unexpected AEs, diabetes mellitus, or new malignancies during treatment.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health
Reference24 articles.
1. Omnitrope®. Highlights of prescribing information. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5&type=display [Accessed 17 Mar 2020]. 2. Grimberg, A, Allen, DB. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr 2017;29:466–71. 3. Richmond, E, Rogol, AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010;18:92–108. 4. Bell, J, Parker, KL, Swinford, RD, Hoffman, AR, Maneatis, T, Lippe, B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95:167–77. 5. Pfäffle, R, Schwab, KO, Marginean, O, Walczak, M, Szalecki, M, Schuck, E, et al.. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 2013;4:3–11.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|